Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (287)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Editorial (3)
  8. Correspondence (2)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (783)
  2. Department of Medicine (783)
  3. Hematologic Malignancies, Division of (783)
  4. Lymphoma (783)
  5. Survivorship Research (233)
  6. Population Sciences Research Program (188)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (187)
  3. Paul Hamlin (186)
  4. Steven Horwitz (168)
  5. David Straus (163)
  6. Maria Palomba (142)

More People

Years
  1. 2025 (6)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis
    Journal Article

    Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma
    Research Letter

    Uppal, M.; Joseph, A.; Drill, E.; Hamlin, P.; Falchi, L.; Noy, A.; Owens, C.; Epstein-Peterson, Z. D.; Salles, G.; Zelenetz, A. D.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma
    Research Letter

    Deschenes-Simard, X.; Pennisi, M.; Perales, M. A.; Shah, G. L.; Zelenetz, A. D.; Yahalom, J.; Imber, B. S.; Santomasso, B. D.; Dahi, P. B.
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
    Journal Article

    Ghione, P.; Bantilan, K. S.; Joffe, E.; Palomba, M. L.; Noy, A.; Caron, P.; Hamlin, P.; Kumar, A.; Matasar, M.; Owens, C.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save